
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical is poised to see significant growth due to recent societal guidelines addressing occupational radiation exposure that make the case for its LIBERTY robotic system stronger. With a proven track record of operator and ergonomic benefits, adoption of LIBERTY is expected to accelerate as operators gain experience using the system. This, coupled with decreasing costs of revenue and international expansion, is expected to lead to margin inflection in 2027 and a competitive advantage in the market. Recent adoption of LIBERTY by Emory Healthcare and strong financial results for 2025 suggest a positive outlook for the company in the future.
Bears say
Microbot Medical is facing significant near-term challenges as their expected adoption has been slower than anticipated, while their monthly cash burn is expected to significantly increase. Additionally, the company's system-level VAC approvals have not been as widespread as initially anticipated, leading to a longer ramp-up period and lower long-term revenue expectations. These factors contribute to the analyst's negative outlook on Microbot Medical's stock.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares